EUCTR2012-004456-11-EE进行中（未招募）不适用
A phase III, randomised, open-label, multicentre, clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su vaccine when administered intramuscularly according to a 0,2-month schedule, a 0,6-month schedule or a 0,12-month schedule in adults aged 50 years or older. - ZOSTER-026
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 354
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •- A male or female aged 50 years or older at the time of the first vaccination.
- •- Written informed consent obtained from the subject.
- •- Female subjects of non-childbearing potential may be enrolled in the study.
- •*Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •- Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •*has practiced adequate contraception for 30 days prior to vaccination, and
- •*has a negative pregnancy test on the day of vaccination, and
- •*has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 230
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 124
排除标准
- •- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, a prednisone dose of < 20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
- •- Administration or planned administration of a live vaccine in the period starting 30 days before and ending 30 days after either dose of study vaccine.
- •- Administration or planned administration of a non-replicating vaccine within eight days prior to or within 14 days after either dose of study vaccine.
- •- Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
- •- Previous vaccination against varicella or HZ (either registered product or participation in a previous vaccine study).
- •- Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
- •- History of HZ.
- •- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g. malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g. medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
- •- Acute disease and/or fever at the time of enrolment.
- •*Fever is defined as temperature = 37.5°C (99.5°F) for oral, axillary or tympanic route, or = 38.0°C (100.4°F) for rectal route. The preferred route for recording temperature in this study will be oral.
- •*Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
- •- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •- Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
- •- Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
- •- Pregnant or lactating female.
- •- Female planning to become pregnant during the entire treatment period and for two months after completion of the vaccination series, or planning to discontinue contraceptive precautions (if of childbearing potential).
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination with Chemotherapy in Patients with HER2-Positive Early Breast Cancer.Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.MedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004897-32-ESRoche Farma S.A. (Soc Unip.) que realiza el ensayo en España y que actúa como responsable de F.Hoffmann-La Roche Ltd.500
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination with Chemotherapy in Patients with HER2-Positive Early Breast Cancer.Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004897-32-BEF. Hoffmann-La Roche Ltd.500
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination with Chemotherapy in Patients with HER2-Positive Early Breast Cancer.EUCTR2017-004897-32-CZF. Hoffmann-La Roche Ltd.500
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination with Chemotherapy in Patients with HER2-Positive Early Breast Cancer.Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004897-32-ITF. HOFFMANN - LA ROCHE LTD.500
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination with Chemotherapy in Patients with HER2-Positive Early Breast Cancer.Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.MedDRA version: 20.0 Level: PT Classification code 10065430 Term: HER-2 positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004897-32-GBF. Hoffmann-La Roche Ltd.500